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Cell membrane receptors rarely work on isolation, often they form oligomeric complexes
with other receptor molecules and they may directly interact with different proteins of the
signal transduction machinery. For a variety of reasons, rhodopsin-like class A G-protein-
coupled receptors (GPCRs) seem an exception to the general rule of receptor–receptor
direct interaction. In fact, controversy surrounds their potential to form homo- hetero-
dimers/oligomers with other class A GPCRs; in a sense, the field is going backward
instead of forward. This review focuses on the convergent, complementary and telling
evidence showing that homo- and heteromers of class A GPCRs exist in transfected
cells and, more importantly, in natural sources. It is time to decide between questioning
the occurrence of heteromers or, alternatively, facing the vast scientific and technical
challenges that class A receptor-dimer/oligomer existence pose to Pharmacology and
to Drug Discovery.
Keywords: dimerization, dopamine receptor, GPCR, homodimer, heteromer, ligands, mammalian receptor, signal
transduction taste receptor
INTRODUCTION
Historical views on any particular topic are both subjective and necessary. In the pre-G-protein-
coupled receptor (GPCR) dimer era, pharmacological approaches of a variety of receptors
attempted to know GPCR function while providing the tools for developing new drugs targeting
GPCRs. Upon cloning, the classical pharmacological approach was challenged by functional studies
in heterologous cells transfected with cDNAs coding for receptors. When the possibility of dimer
occurrence was first suggested (Fuxe et al., 1983; Fuxe and Agnati, 1985) and, afterward, proved
(vide infra), the previous working hypothesis and models were unsuitable to provide answers to
the new questions. Intriguingly, the field is entering now in an unfruitful controversy instead
of facing dimers to change the GPCR molecular physiology and pharmacological paradigms.
Around 10 years after the (Prinster et al., 2005) comprehensive review on “specificity and
functional significance” of GPCR hetero(di)merization and of the first IUPHAR recommendation
on recognition and nomenclature of GPCR Hets, there is a need to reinforce the relevance of GPCR
heteromerization (class A receptors included) for academic and for pharmaceutical purposes.
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Although, GPCR homomerization provides advantages
versus single/monomeric receptors (Banères and Parello, 2003;
Corriden et al., 2014; Gherbi et al., 2015; Marsango et al., 2015),
GPCR heteromerization gives added values for mammalians1,
namely signaling versatility and diversity. For instance, whereas
a dimer of a GPCR coupled to Gi would still be coupled to Gi,
a heteromer constituted by two different receptors may couple
to different signaling pathways than the individual receptors.
Heteromerization in any context, i.e., T cell receptors, taste
receptors, or adrenalin, dopamine, adenosine and opioid GPCRs,
among others, entail selective advantages. As an example,
receptor heteromers (Hets) are needed to taste many different
flavors. Should not class A GPCRs heterodimers exist to provide
a similar extra-added value (Franco, 2009)? One wonders
why evolution could skip this straightforward signal decoding
mechanism, but there is enough evidence to show that it is not
the case. An exhaustive account of the selective advantages of
class A GPCR heteromerization is out of the scope of the present
article. From our laboratory we would select the adenosine A1–
A2A receptor Het, which is a device able to sense the adenosine
concentration and respond via Gi at low concentrations and via
Gs at high concentrations (Ciruela et al., 2006; Ferré et al., 2007;
Cristóvão-Ferreira et al., 2013). From other laboratories it is
very difficult to choose but the coupling of the dopamine D1–D2
receptor Het to Gq (Rashid et al., 2007; So et al., 2007; Hasbi et al.,
2009; George et al., 2014) when individual D1 or D2 receptors
are coupled to, respectively, Gs or Gi, is worth mentioning. Also
relevant is the finding of opioid receptor Hets that explain the
strange pharmacology of opioid receptors and the atypical results
obtained by drugs selectively targeting opioid receptor Hets, and
that has helped to optimize the opioid receptor nomenclature
(Gomes et al., 2000; Portoghese and Lunzer, 2003; Bhushan
et al., 2004; Daniels et al., 2005; Waldhoer et al., 2005; van Rijn
et al., 2010; Yekkirala et al., 2010; Gupta et al., 2014). Those few
examples and the hundreds of already identified Hets contrast
with the existing controversy on class A GPCR heteromerization.
Here, we will first compare the little but convincig evidence for
taste receptor Hets with the similar but unconvincing evidence for
heteromerization of two class A receptors (dopamine D1 and D2).
Later the review selects a few Hets and a few techniques to build
up examples of the varied, complementary and overwhelming
evidence of class A GPCR heteromerization.
MONOMERIC AND DIMERIC TASTE
RECEPTORS versus EVIDENCE FOR
DOPAMINE D1/D2 RECEPTOR Hets
The three basic tastes, umami, sweet and bitter, are sensed
by two types of specialized GPCRs, taste T1 and T22. T1
and T2 receptors are similar to, respectively, class C and
1Actually it would be relevant to check whether heteromerization occurs in
invertebrates and/or in lower vertebrates. Finding any animal Kingdom in
which class A GPCR Hets do not occur would be extremely relevant to prove
heteromerization of class A receptors and to better understand the added value
of Hets.
2www.guidetopharmacology.org
class A GPCRs. IUPHAR indicates that taste T1 receptors are
obligate Hets: “T1R3 acts as an obligate partner in T1R1/T1R3
and T1R2/T1R3 heterodimers, which sense umami or sweet,
respectively. T1R1/T1R3 heterodimers respond to L-glutamic acid
and may be positively allosterically modulated by 5′-nucleoside
monophosphates, such as 5′-GMP [2]3. T1R2/T1R3 heterodimers
respond to sugars, such as sucrose, and artificial sweeteners,
such as saccharin (Nelson et al., 2001).” In this seminal
paper referenced by IUPHAR, Nelson et al. (2001) using an
heterologous expression system report “T1R2 and T1R3 combine
to function as a sweet receptor.” Few years later, Hets for two
class A dopamine receptors (D1 and D2) were identified using
a quite similar experimental approach: “When dopamine D1 and
D2 receptors were coactivated in D1-D2 receptor hetero-oligomeric
complexes, a novel phospholipase C-mediated calcium signal was
generated” (So et al., 2007). For both T1R1/R2/R3 and D1–D2
Hets, calcium mobilization was used as read-out, transfecting
an engineered G protein in the case of taste receptors, and
taking profit of endogenous Gq expressed in HEK-293T cells in
the case of dopamine receptors. In the report of taste receptor
heteromerization, transiently transfected cells were used, and in
the report of dopamine receptor heteromerization, cells stably
expressing D1 and D2 receptors were employed. Whereas taste
T1 and class C GPCRs are considered Hets, class A receptor
dimerization in general, or dopamine D1–D2 receptor Hets in
particular are questioned in articles with titles such as: “GPCR
dimers fall apart” (Lambert, 2010) or “Evidence against dopamine
D1/D2 receptor heteromers” (Frederick et al., 2015). Reinforcing
the idea of class A GPCR heteromerization is now due.
Class A taste T2 receptors are another example of the criteria
used to accept dimerization. Although T2 receptors are often
depicted as two molecules interacting together, IUPHAR does not
support the dimeric view of these receptors. The main reason
for such differential criteria is the big extracellular portion in
T1. In fact, the most important difference between class A and
C GPCRs is that the last ones have large extracellular agonist
binding domains that may dimerize even in the absence of the
rest of the receptor molecule (Kunishima et al., 2000; Romano
et al., 2001; Kawahara et al., 2012). In contrast, the extracellular
N-terminal domain of rhodopsin-like GPCRs is too short to be
relevant for GPCR dimer formation. Historically, the discovery
of class A GPCR dimers started by taking advantage of techniques
used in the Immunology field for detecting interactions between
membrane proteins, being the T-cell receptor one of the best
studied (Figure 1). In this sense, antibody generation and co-
immunoprecipitation constituted a revolution in Immunology
and served to build up a molecular framework to understand
antigen recognition and cell responses. Antibodies raised against
GPCRs served to identify GPCRs by immunoblotting, and to
label them in cells and tissues. They were also instrumental to
identify homo- and heterodimers by immunoblotting and co-
immunoprecipitation (Ciruela et al., 1995; Franco et al., 1996;
Ginés et al., 2000; Gomes et al., 2000) and, more recently,
3Apparently, the linked reference (Li et al., 2002: prostaglandin receptor EP2
mediates PGE2 stimulated hypercalcemia in mice in vivo) does not match the
information related to taste receptors.
Frontiers in Pharmacology | www.frontiersin.org 2 March 2016 | Volume 7 | Article 76
fphar-07-00076 March 31, 2016 Time: 15:2 # 3
Franco et al. Class A GPCR Dimers
FIGURE 1 | Schematic representation of the T-cell receptor-CD3
complex. The heterocomplex is formed by variable TCR-α and TCR-β chains
coupled to three dimeric signaling transduction modules CD3δ/ε, CD3γ/ε and
CD3ζ/ζ or CD247. CD3, Cluster of differentiation 3; CD247, cluster of
differentiation 247 or CD3ζ/ζ; ITAM, immunoreceptor tyrosine-based activation
motif; TCR, T-cell receptor.
by proximity ligation assays (Borroto-Escuela et al., 2011,
2012). Other techniques that are not based on antigen-antibody
recognition have confirmed these early findings on GPCR homo-
and heteromerization.
THE CONTROVERSY SURROUNDING
RHODOPSIN-LIKE CLASS A
G-PROTEIN-COUPLED RECEPTOR
HETEROMERIZATION
The hypothesis of dimerization/oligomerization of GPCRs for
neurotransmitters was put forward by Fuxe et al. (1983, 1987).
However, technical difficulties prevented the discovery of GPCR
dimers until the end of the 20th Century. Apart from diverse
evidence on receptor homodimerization, and for demonstration
that heteromerization was needed for cell surface expression and
for GABAB receptor function (White et al., 1998), identification
of first class A heterodimers came when Gomes et al. (2000)
reported the first Het for two subtypes of opioid receptors µ and
δ and when Ginés et al. (2000) identified the first Het of two
receptors for two different neurotransmitter/neuromodulators,
namely the adenosine A1 and dopamine D1 receptor Het.
As of 2014 the number of interactions between GPCRs was
537 (Borroto-Escuela et al., 2014). Proved contradictory results
constitute approximately 1% of the total Hets, i.e., 5–10, and these
exceptions have been reported in a given model but not found
in a different model or using another assay type (Fuxe et al.,
2014). This very low percentage of inconsistencies substantiates
that GPCR and in particular class A GPCR receptor–receptor
interactions appear as a robust discovery.
According to the rules of http://www.merriam-webster.com,
the belief that GPCRs -or else- are monomers may be referred
to as: monomerism. The Whorton et al. (2007) report was
instrumental for a certain consolidation of this phenomenon.
The authors showed that, in an artificial system, monomeric β2-
adrenergic receptors may activate the coupled G protein. Such
article has been frequently used in reviews and in thematic
meetings to reinforce the idea that class A GPCRs should be
monomers. On the one hand, it is likely that the lipoprotein
particles used in the assays could not accommodate two GPCR
molecules together to study differential properties of monomers
versus homo- or hetero-dimers. On the other hand, an in vitro
demonstration cannot be used to be certain about receptor
operation in vivo. Neither the Whorton et al. (2007) data
may scientifically substantiate authors’ assertion “cooperativity
of agonist binding is due to G protein association to the receptor
monomer and not receptor oligomerization.” Cooperativity in the
binding of ligands to receptor monomers is an oxymoron since
this phenomenon requires a dimer or a trimer or a higher-
order macromolecule with more than one orthosteric site. In
what concerns cooperativity by class A GPCR homomers, two
reports using fluorescent ligands to adenosine A3 receptors in
transfected cells, a challenging technological approach and a
solid theoretical formulation and data analysis (May et al., 2011;
Corriden et al., 2014), constitute solid grounds to interpret
biphasic curves as cooperativity on ligand binding to orthosteric
centers in a receptor dimer. Data from radioligand binding
assays may provide not only evidence for homomer but for Het
formation (Birdsall, 2010). The reluctance to accept class A GPCR
dimers may be also challenged taking advantage of both structural
information and interpretation of pharmacological data from
similarly basic but powerful approaches.
ARE THERE GPCR MONOMERS?
STRUCTURAL DATA FAVORING CLASS A
GPCR HOMODIMERS
The word “monomer,” often used in the GPCR research field
is defined by [Encyclopædia Britannica, Inc.] as “a molecule
of any of a class of compounds, mostly organic, that can react
with other molecules to form very large molecules, or polymers.
The essential feature of a monomer is polyfunctionality, the
capacity to form chemical bonds to at least two other monomer
molecules. Bifunctional monomers can form only linear, chainlike
polymers, but monomers of higher functionality yield cross-
linked, network polymeric products.” On the one hand, this
definition of a monomer built on solid chemical knowledge
should be considered in the field. On the other hand, even
assuming that a given GPCR may act in “isolation” and far
from other GPCRs, they are not monomers as they interact,
at least, with heterotrimeric G proteins. Therefore, the real
issue is whether or not class A GPCRs may interact with other
class A GPCRs while they already interact with a whole bunch
of other proteins. Furthermore, the nomenclature for GPCRs
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is confusing; probably an appropriate definition of “GPCR
molecule” is needed.
The big N-terminal extracellular domain of class C receptors
allows formation of crystals constituted by dimers of the
extracellular domain; in contrast, the N-terminal domain of class
A is very short and unable to form such dimers. This difference
in the size of the N-terminal extracellular domain seems to be the
only reason that dopamine receptors may not form dimers and
that class A T2 taste receptors may not form dimers whereas class
C T1 taste receptors do. Due to the overwhelming evidence for
class A GPCR homo/heteromerization, it may well happen that
dimerization is guided by transmembrane domains and not by
extracellular domains. To our knowledge no study on the relative
positions of extracellular versus transmebrane domains has been
performed. In the absence of such studies, fixing the dimeric
structure of the extracellular domains does not provide any clue
on the position of the transmembrane domains of the interacting
receptors, i.e., useful information on the quaternary structure of
the overall class C GPCR dimer complexes is missing.
Difficulties arising from crystallization of membrane proteins
have been sorted out for GPCRs using an approach that, in brief,
consists of molecules containing transmembrane helices fused to
proteins such as T4 lysozyme or thermostabilized apocytochrome
b562, which favor crystal formation. Structures from X-ray
diffraction data usually assume a monomer as the basic unit.
Such interpretation was sanctioned by the finding that arrays of
rhodopsin itself in crystals was antiparallel to the plane of the
membrane (Edwards et al., 2004; Li et al., 2004), something that
is not seemingly physiological but that was not found in other
solved rhodopsin structures showing parallel arrangements (vide
infra).
Subsequent studies, however, have developed crystals in
which GPCR dimers exist in the correct -parallel- orientation.
The obligate interfaces occurring in 3D GPCR structures (see
Cordomí et al., 2015) may not reflect real inter-protomer
interfaces of a dimer in its native conformation in the
cell surface, but the finding of two neighbor molecules in
GPCR crystals compatible with the arrangements of dimers in
biological membranes should be considered as relevant. Different
transmembrane helices, often in a head-to-head interacting mode
(Cordomí et al., 2015) do participate in the parallel receptor
dimer arrangement in a variety of class A GPCR crystals, from
activated rhodopsin (Salom et al., 2006), to CXCR4 chemokine
(Wu et al., 2010) and κ- or µ-opioid receptors (Manglik et al.,
2012; Wu et al., 2012). Parallel association of receptors have also
been described in crystals of β2-adrenoceptors (Cherezov et al.,
2007). As Wu et al. (2012) pointed out: “While the existence of
GPCR dimers in vivo and their physiological relevance remain
highly debatable, several distinct potential dimer interfaces are
starting to emerge from crystallographic and biochemical studies.”
Noteworthy, µ-opioid receptor bound to a morphinan
antagonist crystalizes as a dimer with an interface containing
a four-helix bundle motif formed by transmembrane domains
5 and 6 (Manglik et al., 2012). Shortly afterward, the 3D
structure of ligand-free turkey β1-adrenergic receptors in a lipid
membrane-like environment exhibited oligomers constituted by
two alternating dimer interfaces, one involving transmembrane
helices 4 and 5 and the other engaging transmembrane helices
1 and 2 and the first extracellular loop (Whorton et al., 2013).
Last but not least, the seven transmembrane domain of the
smoothened SMO receptor crystalizes as a parallel dimer. Despite
its relatively small similarity with class A GPCRs, the SMO
receptor shows a high degree of spatial conservation of the
transmembrane bundle and, also, structural correspondences in
the intracellular domains with the solved class A GPCR structures
(Wang et al., 2013). These structural features in SMO and class
A receptors have led to the suggestion to translate the class A
numbering nomenclature (Ballesteros and Weinstein, 1995) to
class F GPCRs (Wang et al., 2013).
Lacking yet is any structural data concerning Hets. Precisely,
one of the challenges in the GPCR field is Het crystallization,
irrespective of whether Hets are constituted by class A or class
C receptors. In fact, class C heteromerization has a long way to
go; as earlier-mentioned it is not known whether dimerization
of the N-extracellular domain conditions the transmembrane
intra-dimer interactions. It is possible that the hinge between
the N-terminal and the first transmembrane domain loses its
conformational flexibility upon dimerization. In other words,
it is not known whether transmembrane domains may bring
two class C receptors together independently of N-terminal-
domain dimerization, i.e., may a given class C Hets have in the
membrane more than one quaternary structure? May different
dimer structures be established by simultaneously involving
either transmembrane regions or the N-terminal domains?
Actually, class C Hets raise more structure-related questions than
putative class A Hets.
G-PROTEIN-COUPLED RECEPTORS IN
HETEROLOGOUS SYSTEMS AND
KNOCKOUT MICE
Adrenalin receptors were, and still are, a reference in the GPCR
research field. Pioneering studies were centered on adrenergic
receptors in natural sources, e.g., isolated heart membranes,
but this methodology was almost completely displaced by work
in heterologous systems. In fact, COS- or CHO-transfected
cells expressing the GPCR have been widespread used to know
the whereabouts of these receptors and the scientific advance
has been paramount and deserving the 2012 Nobel Prize in
Chemistry, awarded to Drs Lefkowitz and Kobilka.
Identification of GPCR dimers occurred in parallel in
transfected cells and in samples from natural sources.
Biophysical-based methodologies such as fluorescence (FRET) or
bioluminescence (BRET) energy transfer have been instrumental
to show homo- or hetero-dimers in living transfected cells.
A combination of FRET and BRET [sequential resonance energy
transfer (SRET); Carriba et al., 2008] has allowed detection of
GPCR trimers, and a combination of BRET with molecular
complementation, using GPCRs fused to complementary
hemiproteins of donor/acceptor BRET pairs, permits detection
of tetramers (Cristóvão-Ferreira et al., 2013; Bonaventura
et al., 2015). One of the issues raised by monomerism is the
high-amount of receptors present in transfected cells that may
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“force” dimer, trimer, etc. formation. By the same token, it
could be argued that many of the relevant findings in the last
30 years should be questioned as they have been obtained in
heterologous systems overexpressing the receptors. What is
more relevant, membranes used in drug screening usually come
from GPCR-overexpressing transfected cells that likely express
dimer and higher-order structures, therefore, the screening is
to, at least, homodimers. Consequently, one may wonder why
tools available for receptor dimers, as the two-state dimer model
(Franco et al., 2005, 2006; Casadó et al., 2007, 2009a,b), are
not used for data analysis; it provides more robust parameters
than alternative models such as the two-independent site, which
assumes one high affinity and one low-affinity population
of monomeric receptors. More importantly, should not the
previous knowledge be revisited if, as monomerism predicts,
GPCRs in the heterologous systems are forced to express
dimers?
Remarkably, many of the studies describing dimers have
attempted and succeeded in proving their occurrence in
natural sources. The literature identifying and proving Hets in
natural sources is extensive and this review is not intended
to exhaustively address it. The occurrence of Hets in natural
sources, however, should be taken into account when analyzing
data from transgenic animals defective in a given GPCR.
GPCRs are somewhat promiscuous in their interaction with
other GPCRs4 (Borroto-Escuela et al., 2014). Therefore, any
particular phenotype in one of these knockout animals is
not simply due to the lack of the GPCR but to the lack
of the Hets in which the GPCR participates. In this context,
pharmacologists may stick to naïvely assign a phenotype to
the lack of a monomer or take the lead in searching the tools
needed to correlate a given phenotype with a particular receptor
Het.
DIMER-MEDIATED AGONIST AFFINITY
MODULATION AND
CROSS-ANTAGONISM
Activation of class A GPCRs results in signal transduction,
meaning that agonist binding to the GPCR induces
conformational changes that are transmitted toward the
interior of the cell. Data from radioligand binding assays have
confirmed one of the predictions of Het formation, namely the
agonist-induced changes of affinity upon binding of a second
agonist to the partner receptor in a receptor heterocomplex
(Birdsall, 2010). In some cases, such modulation may be of
physiological relevance as occurs in the serotonin 5HT2A
and metabotropic glutamatergic 2 receptors (González-Maeso
et al., 2008). In other cases the phenomenon may reflect dimer
formation but the change in affinity is too small to be operating
in vivo.
Agonist affinity cross-modulation suggests Het formation
but it may not reflect a direct receptor–receptor interaction.
As G proteins remain attached to GPCRs in the membrane
4www.gpcr-hetnet.com
preparations used for radioligand binding, agonist-induced
conformational changes in a G protein coupled to one GPCR
may indirectly affect a second receptor that is not directly
interacting with the first one. By contrast, antagonists and inverse
agonists are molecules that bind to GPCRs and inhibit agonist-
induced signaling. Very consistently, the selective antagonist of
a receptor blocks the signal transduction induced by the agonist
binding to the partner heteroreceptor. This counter intuitive
fact may be explained by heteromerization. The phenomenon
has been described in a variety of GPCR Hets such as
orexin/corticotropin-releasing factor receptor (Navarro et al.,
2015), dopamine D1/histamine H3 (Moreno et al., 2011) or
angiotensin II AT1/dopamine D2 (Martínez-Pinilla et al., 2015)
receptor Hets. The Ockham’s razor or law of parsimony states
“pluralitas non est ponenda sine necessitate.” Accordingly, if a
convoluted indirect mechanism is not necessary, the simplest
explanation is provided by a GPCR Het framework in which the
antagonist fixes a non-productive conformational state in one
receptor that also impedes the activation of the partner receptor
in the Het. Indeed, cross-antagonism should be considered as
a tool of heteromer identification. Usually, cross-antagonism is
first demonstrated in heterologous cells co-expressing the two
receptors and constitutes a so-called Het print. Subsequently,
dimer occurrence may be investigated on looking for the
Het print in samples from mammalian tissues/organs. GPCR-
induced activation of the MAP kinase pathway(s) is a successful
readout for detecting cross-antagonism, for instance in the
central nervous system, both in fresh slices from brain regions
and primary cultures of neurons or glia (Balenga et al., 2014;
Martínez-Pinilla et al., 2014, 2015).
BIVALENT PROBES
The affinity of a given agonist for a given GPCR may change if
the receptor is forming Hets (Ferré et al., 2009). Het-selective
ligands were then searched for both, detecting Hets in vivo
and as conceptually novel therapeutic tools. One example is 6′-
guanidinonaltrindole, a opioid-receptor-Het selective drug, that
in preclinical studies showed analgesia only if administered in the
parts on the central nervous system where δ–κ-opioid receptor
Hets are expressed. The result was also a proof-of-concept for
tissue-selective drug targeting (Waldhoer et al., 2005).
Another strategy of selectively targeting homo- or
heterodimers is to synthesize bivalent compounds able to
simultaneously bind the two receptors in a GPCR dimer. These
molecules consist of two agonist/antagonist moieties separated
by spacers of variable length. Therefore, two orthosteric sites may
be bridged by a bivalent ligand if the two pharmacophores are
appropriately designed. The capacity of simultaneous binding
to two different orthosteric sites is an added value that may
be used to detect receptor dimers (Figure 2). A very detailed
review on the various possibilities of bivalent ligands for the
characterization of GPCR dimers is provided by Hiller et al.
(2013). Certainly, emerging structural information will help
revisit data on bivalent compounds to be sure of whether
the linkers have the appropriate length to allow simultaneous
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FIGURE 2 | Scheme of the simultaneous binding of bivalent ligands with linkers of appropriate length to two receptors in a GPCR dimer. The
agonist/antagonist moieties of the bivalent ligand are selective for their respective receptors (orange for GPCR-I, green for GPCR-II) and are linked by an spacer.
(A) Binding to two equal GPCRs forming an homodimer. (B) Binding to two different GPCRs forming an heterodimer. A full account of the possibilities of binding of
bivalent ligands to GPCRs is provided by Brogi et al. (2014).
binding to the two receptors in a given homo- or heterodimer
(see Glass et al., 2016).
Synthesis of bivalent ligands for GPCRs was performed in
the pioneering report of Halazy et al. (1996), years before
GPCR heterodimerization was reported. The authors concluded
that their results support: “. . .the hypothesis that the important
increase in potency of the serotonin dimers can be attributed
to the presence of two serotonin pharmacophores in the same
molecule.” Binding of those molecules to one orthosteric site
cannot provide any increase in affinity or potency but dimers
were not yet seriously considered at that time. It should be
also pointed out that as early as in 1982 dimeric peptide
enkephalins were synthesized and Shimohigashi et al. (1982)
proved their interaction with two δ- but not with two µ-opioid
receptors. To explain their results authors took advantage
of another phenomenon that, by the way, may occur upon
agonist activation, namely receptor clustering (Franco et al.,
1996). As dimers for opioid receptors were not yet described,
authors assumed that bivalent ligands were simultaneously acting
in two close receptors within receptor clusters. Qualitatively
similar results were obtained by Carrithers and Lerner (1996)
that found bivalent ligands for alpha-melanocyte stimulating
hormone receptors more potent than monovalents. Rationale
for the study was that “multivalency can increase the apparent
affinity of a ligand for its binding site” but the authors aimed at
designing bivalent ligands “to bind to two adjacent receptor sites.”
Multivalence of ligands together with dimer occurrence do fit
with these pioneering results.
Russo et al. (2007) designed bivalents ligands that were able
to bind, in transfected cells, to serotonin 5-HT4 constitutive
receptor dimers identified by Berthouze et al. (2005). To our
knowledge these compounds were not used to address the
occurrence of direct 5-HT4 receptor–receptor interactions in
natural sources. The differential binding to human dopamine
D2 receptor of bivalent and monovalent ligands also suggested
the occurrence of homodimers in transfected cells (Kühhorn
et al., 2011a,c). As the theory of ligand binding to receptors
would predict, the Hill coefficient of competition curves using a
radiolabeled antagonist, [3H]spiperone, was 2 for (homo)bivalent
and 1 for monovalent molecules (Kuhhorn et al., 2011b).
In Portoghese’s laboratory, the bivalent drug approach was
successfully used in vitro -in living cells- and in natural sources,
but also in behavioral models. Few years after the reporting of
the first class A GPCR Hets, bivalent ligands containing δ- and
κ-opioid antagonist moieties, provided evidence in the spinal
cord of Hets formed by δ-κ-opioid receptors (Bhushan et al.,
2004). Remarkably, these Hets explain the atypical pharmacology
found for opioid GPCR subtypes in some areas of the central
nervous system (Daniels et al., 2005), thus suggesting the
occurrence of these receptor Hets in natural sources.
Also consistent with in vivo occurrence of µ-opioid/
chemokine 5 receptor Hets, selective Het targeting may
significantly reduce neuropathic and inflammatory pain (Akgün
et al., 2013; Smeester et al., 2014). Although, the therapeutic
use of bivalents to combat pain is limited due to the
low chances of efficient crossing the blood brain barrier,
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these results are impotant to confirm Hets occurrence in vivo.
Performing radioligand binding experiments in samples from
tissues, and comparing competition curves of bi- and monovalent
drugs could indeed prove or disprove the existence of dimers
in mammals. In summary, heterobivalent ligands, i.e., molecules
having two different moieties with a linker of appropriate length,
are ad hoc probes for detecting GPCR Hets in natural sources.
In a detailed and careful study, Soriano et al. (2009)
designed, synthesized and tested bivalent ligands containing both
adenosine receptor agonist and dopamine receptor antagonist
pharmacophores. Molecules with the appropriate spacer length,
which was compatible with simultaneous binding to the
two receptors, bound (in co-transfected cells) dopamine D2
and adenosine A2A receptors with higher affinity than their
monovalent counterparts. This finding in cells coexpressing
the two receptors was similarly detected in membranes from
brain striatum. Those adenosine-dopamine bivalents did not
bind with higher affinity to membranes expressing only one
of the receptors. Modeling studies indicated that appropriate
linker lengths were consistent with simultaneous binding to
D2 and adenosine A2A receptor dimers. More importantly,
the results from competition assays using specific radioligands
(for adenosine or for dopamine receptors) can only be
explained if there is simultaneous binding to dimers. Basic
pharmacology indicates that simultaneous binding of bivalents
to two binding sites, should be characterized by higher affinity
than the monovalent control compounds. In fact, binding
of one moiety to one binding site increases the effective
local concentration available to the binding site in a partner
receptor.
In summary, despite the field seems not yet mature to fully
accept class A GPCR homo/heteromerization, data have been
stubborn on providing evidence of the phenomenon. The models
used have been very diverse and the techniques have been
from co-immunoprecipitation all the way to powerful energy
transfer in vitro and ex vivo assays and in vivo transactivation
using transgenic mice (Rivero-Müller et al., 2010; Jonas et al.,
2013; Grzesik et al., 2014). Class A receptor complexes have
also been visualized in tissues by means of atomic force
microcopy (Fotiadis et al., 2006; Cordomí and Perez, 2009),
confocal fluorescence resonance energy transfer (So et al.,
2007; Albizu et al., 2010; Perreault et al., 2010; Verma et al.,
2010). Moreover, their occurrence, deduced from the avidity of
peptides derived from class A GPCRs primary structure to bind
together, has been detected by definitive methods5 such as mass
spectrometry (Ciruela et al., 2004; Navarro et al., 2010), not to
mention the positive results from surface plasmon resonance
or recently-developed imaging techniques (e.g., fluorescence
cross-correlation spectroscopy) able to detect dimer/oligomer-
containing single particles.
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